{
    "componentChunkName": "component---src-templates-blog-post-js",
    "path": "/posts/de8d3ae662fe11ecb4996f5ba193d428/",
    "result": {"data":{"allMysqlLists":{"edges":[{"node":{"title":"AstraZeneca, Oxford aim to produce Omicron-targeted vaccine","status":1,"alt":"","src":"https://www.rnz.co.nz/assets/news_crops/133902/eight_col_075_widak-covid19v211021_npOPZ.jpg?1637028579","source":"rnz","menu":"world","local_src":"","load_img":"","img_url":"https://www.rnz.co.nz/assets/news_crops/133902/three_col_075_widak-covid19v211021_npOPZ.jpg?1637028579","href":"https://www.rnz.co.nz/news/world/458451/astrazeneca-oxford-aim-to-produce-omicron-targeted-vaccine","description":"AstraZeneca Plc said it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specificâ€¦","country":"nz","create_time":"2021-12-22T00:13:34.000Z","content":"[\"AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine.\", \"<img src=\\\"https://www.rnz.co.nz/assets/news_crops/133902/eight_col_075_widak-covid19v211021_npOPZ.jpg?1637028579\\\" alt=\\\"An illustrative image of a person holding a medical syringe and a vaccine vial in front of the Astra Zeneca logo displayed on a screen.\\r\\nOn Thursday, October 21, 2021, in Edmonton, Alberta, Canada.\\\" class=\\\"abcImg\\\"></img>\", \"<div class=\\\"imgText\\\">\\nFile photo. \\nPhoto: AFP\\n</div>\", \"\\\"Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data,\\\" a spokesperson for the company said in a statement.\", \"Oxford did not immediately respond to a request for comment outside business hours.\", \"The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford.\", \"\\\"Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realised,\\\" Douglas told FT.\", \"A lab-study last week found that AstraZeneca's antibody cocktail Evusheld retained neutralising activity against the Omicron variant.\", \"Vaccine makers Pfizer/BioNTech and Moderna also previously said they were working on Omicron-specific Covid-19 vaccines. Moderna said hopes to start clinical trials early next year.\", \"- Reuters\"]","href_hash":"de8d3ae662fe11ecb4996f5ba193d428"}}]}},"pageContext":{"slug":"de8d3ae662fe11ecb4996f5ba193d428"}},
    "staticQueryHashes": ["3649515864","764694655"]}